In our opinion, upregulated levels of AFAP1-AS1 could be a selective prognostic and therapeutic marker for the ESCC patients treated with cisplatin, 5-FU, and paclitaxel. The gene discussed is AFAP1; the disease is esophageal squamous cell carcinoma.